Milan, June 18th , 2015 – A new study carried out by Italian researchers at the Department of Surgery and Translational Medicine, University of Florence demonstrates that supplementation with Meriva®, the Indena proprietary lecithin-based delivery system of curcumin, may be effective as a complementary support in skin disorders management.
In this single-dose, randomized, double-blind, placebo-controlled study sixty-three subjects with mild-to-moderate psoriasis vulgaris (PASI <10) were randomly divided into two groups treated with topical steroids and orally with Meriva®, or with topical steroids alone, both for 12 weeks. Researchers measured the quality of life and health benefits and the effects of the treatment on the serum levels of IL-17 and IL-22 that are thought to play a major role in this disorder.
Data from the study demonstrated that Meriva® may be regarded as a safe and well-tolerated supplementation for the complementary support to subjects treated with topical steroids. Among the several biological effects of curcumin, the ability to downregulate the T cell-mediated process, and in particular the Th22 pathway, may be considered one of the major mechanisms by which Meriva® supports skin dysfunction recovery.
Antonella Riva, Senior Scientific Researcher at Indena, commented: “We welcome the promising results of Meriva® in this new area, and the chance to improve the quality of life for people affected by this troublesome condition”.
Psoriasis is a common chronic inflammatory disease affecting the skin, the nails and the joints of 125 million people, corresponding to about 3% of the world’s population, with a significant impact on long-term quality of life.
 Idem, References 27-33.
 IFPA – International Federation of Psoriasis Associations, Facts about psoriasis, available at http://www.worldpsoriasisday.com/web/page.aspx?refid=130
 J. M. Gelfand, S. R. Feldman, R. S. Stern, J. Thomas, T. Rolstad, and D. J. Margolis – Journal of the American Academy of Dermatology, vol. 51, no. 5, pp. 704-708, 2004.
Meriva® is a patented delivery form of curcumin utilizing Indena proprietary Phytosome® technology, for healthy inflammatory response and joint health. Pharmacokinetic comparison studies have shown Meriva® to improve the bioavailability of curcuminoids about 30-fold and give significant absorption benefits. The product is supported by 18 clinical trials demonstrating effectiveness for joint and bone health and inflammatory response support.
Further info on Meriva® and other Phytosome®s: www.phytosome.info
Want to know more about Phytosome® technology?
Watch the video “Phytosome®: The technology explained” on the Indena YouTube channel
Follow us on Twitter: @IndenaSpA
Please note that the physiological activity of the ingredient described herein is supported by the referenced clinical trial reports. Marketers of finished products containing the ingredient described herein are responsible for determining whether the claims made for such products are lawful and in compliance with the laws of the country in which they will market the products.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.